News

The artists Elisabetta Citterio and Claudia Cagliano have created portraits of nearly 60 female researchers from nine countries. Twenty-five of them can be viewed in the "STEM Passion" exhibition until March 12, 2024 in the Rahel Hirsch Center for Translational Medicine Berlin.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

Simon Haas has been awarded the Lisec-Artz Prize, endowed with €10,000, for his single-cell analysis of communication between stem and immune cells in blood cancer. The University of Bonn Foundation established this prize to honor outstanding early-career cancer researchers.

A data gap that threatens timely diagnosis and treatment for half the population, the visibility of female researchers in Wikipedia, and myriads of microbes in and on our bodies – the Max Delbrück Center's program for the Berlin Science Week 2023 is focused on dimensions of diversity.

Cryo-electron microscopy allows structural biologists to look at the most minute building blocks of life. We celebrated the opening of the joint Core Facility and the corresponding research building of Charité – Universitätsmedizin Berlin and the Max Delbrück Center with a symposium.

Internationally renowned for pioneering achievements and geared to inter-institutional cooperation: 22 research groups at the Berlin Institute for Medical Systems Biology in the Max Delbrück Center (MDC-BIMSB) explore how genes regulate life. It is now celebrating its 15th birthday.

Bartter syndrome type 3 is the result of several structural variants in the genome. By using long-read sequencing, Janine Altmüller and her team from the Max Delbrück Center, the BIH and University Hospital Cologne mapped out the rare disease in unprecedented detail. They have now reported their findings in “Genome Medicine.”

Cancer cells are capable of escaping chemotherapy and radiotherapy by activating a signaling pathway that prevents them from dying. Researchers led by Claus Scheidereit at the Max Delbrück Center have now described in Cell Chemical Biology two new compounds that block this escape route.

The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will start in the fall.

Some T cells of the immune system are especially sensitive to genetic disturbances within their mitochondrial power plants. Scientists from BIH and Max Delbrück Center have now published their findings in the journal “Nature Genetics”.